RxDoctor Payments Data

Matthew du Mont, MD

Urology · Fredericksburg, VANPI 1215982715

Payments from drug & device makers

$4,566in general payments, 2019–2025

Across 202 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$605
  • Dornier Medtech America, Inc$476
  • Johnson & Johnson$469
  • Pfizer$424
  • Dendreon Pharmaceuticals LLC$301
  • Axonics, Inc.$228
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,18992%
  • Education$3778%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,566 in reported general payments places this provider in the 60th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$237,497
Medicare patients
613
Services billed
3,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$375,064
MyrbetriqMirabegron122$105,521
GemtesaVibegron54$59,250
OrgovyxRelugolix12$33,478
Tamsulosin Hcl437$5,823
Finasteride443$5,547
Mirabegron ErMirabegron12$4,849
NitrofurantoinNitrofurantoin Macrocrystal105$2,767
Methenamine Hippurate23$2,512
Estradiol33$1,740
Testosterone24$1,612
Testosterone Cypionate22$1,415
Cephalexin34$1,055
Dutasteride27$725
Oxybutynin Chloride ErOxybutynin Chloride21$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$605$480,584149 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$148$92,72866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 300 urology providers in Virginia.

Other urology in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →